中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

长期恩替卡韦治疗对慢性乙型肝炎患者肾功能的影响

张青 张飙 王培 李颍 颜学兵 丁芹

引用本文:
Citation:

长期恩替卡韦治疗对慢性乙型肝炎患者肾功能的影响

DOI: 10.3969/j.issn.1001-5256.2020.07.010
基金项目: 

国家自然科学基金资助项目(81371867); 

详细信息
  • 中图分类号: R512.62

Influence of long-term entecavir treatment on renal function in patients with chronic hepatitis B

Research funding: 

 

  • 摘要: 目的探讨长期应用ETV抗病毒治疗对慢性乙型肝炎(CHB)患者肾功能的影响。方法回顾性分析2015年1月-2019年6月在淮安市第四人民医院接受ETV抗病毒治疗半年以上的CHB患者232例。按不同性别、年龄(<或≥65岁)、有无肝硬化和肾小球滤过率(e GFR)(<或≥90 ml·min-1·1.73 m-2)分组,探讨各个亚组的ETV治疗前后的肾功能指标[血尿素氮(BUN)、血肌酐(Scr)和e GFR]变化情况。并比较ETV抗病毒方案在抗病毒前后总体ALT、AST、Alb、HBs Ag、HBV DNA和肾功能指标(BUN、Scr和e GFR)变化。采用全自动生化分析仪检测血生化指标,包括ALT、AST、Alb、BUN、Scr和e GFR,采用实时荧光定量PCR法检测HBV DNA,采用罗氏电化学发光法检测血清HBs Ag定量。正态分布的计量资料组间比较采用配对t检验,非正态分布的计量资料组间比较采用Wilcoxon秩和检验,采用二分类logistic回归分析筛选ETV抗病毒治疗后e GFR <90 ml·min-1·1. ...

     

  • [1]IDILMAN R.Management of special patient groups with hepatitis Bvirus infection:The EASL 2017 clinical practice guidelines[J].Turk J Gastroenterol,2017,28(6):518-521.
    [2]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J].J CIin Hepatol,2015,32(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,32(12):1941-1960.
    [3]OU H,CAI S,LIU Y,et al.A noninvasive diagnostic model to assess nonalcoholic hepatic steatosis in patients with chronic hepatitis B[J].Therap Adv Gastroenterol,2017,10(2):207-217.
    [4]CAI SH,LU SX,LIU LL,et al.Increased expression of hepatocyte nuclear factor 4 alpha transcribed by promoter 2 indicates a poor prognosis in hepatocellular carcinoma[J].Therap Adv Gastroenterol,2017,10(10):761-771.
    [5]YANG YM,CHOI EJ.Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection[J].Ther Clin Risk Manag,2017,13:1273-1285.
    [6]LIM L,THOMPSON A,PATTERSON S,et al.Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy[J].Liver Int,2017,37(6):827-835.
    [7]YANG X,MA Z,ZHOU S,et al.Multiple drug transporters are involved in renal secretion of entecavir[J].Antimicrob Agents Chemother,2016,60(10):6260-6270.
    [8]CIHLAR T,HO ES,LIN DC,et al.Human renal organic anion transporter 1(h OAT1)and its role in the nephrotoxicity of antiviral nucleotide analogs[J].Nucleosides Nucleotides Nucleic Acids,2001,20(4-7):641-648.
    [9]MANDKOVJ,VOLKOVM,PVEK P,et al.Entecavir interacts with influx transporters h OAT1,h CNT2,h CNT3,but Not with h OCT2:The potential for renal transporter-mediated cytotoxicity and drug-drug interactions[J].Front Pharmacol,2015,6:304.
    [10]FUJII T,KAWASOE K,OHTA A,et al.A case of entecavir-induced Fanconi syndrome[J].CEN Case Rep,2019,8(4):256-260.
    [11]WU IT,HU TH,HUNG CH,et al.Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia:A retrospective cohort study[J].Clin Microbiol Infect,2017,23(7):464-469.
    [12]WU X,CAI S,LI Z,et al.Potential effects of telbivudine and entecavir on renal function:A systematic review and meta-analysis[J].Virol J,2016,13:64.
    [13]LIN YS,SHIH SC,WANG HY,et al.Comparison of telbivudine and entecavir on the change of off-treatment e GFR after 3 years of treatment in non-cirrhotic chronic hepatitis B patients[J].BMC Gastroenterol,2017,17(1):22.
    [14]HE P,ZHANG D,LI H,et al.Hepatitis B virus X protein modulates apoptosis in human renal proximal tubular epithelial cells by activating the JAK2/STAT3 signaling pathway[J].Int J Mol Med,2013,31(5):1017-1029.
    [15]ZHANG JB,GUO HH.Research advances in hepatitis B cirrhosis with renal injury and the application of antiviral drugs[J].J CIin Hepatol,2019,35(1):191-196.(in Chinese)张洁冰,郭宏华.乙型肝炎肝硬化合并肾损伤及抗病毒药物的应用[J].临床肝胆病杂志,2019,35(1):191-196.
    [16]ZHENG S,LIU L,LU J,et al.Efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B virus infection:A 2-year prospective study[J].Medicine(Baltimore),2019,98(42):e17590.
    [17]NEUGARTEN J,ACHARYA A,SILBIGER SR.Effect of gender on the progression of nondiabetic renal disease:A meta-analysis[J].JAm Soc Nephrol,2000,11(2):319-329.
    [18]BRAR A,MARKELL M.Impact of gender and gender disparities in patients with kidney disease[J].Curr Opin Nephrol Hypertens,2019,28(2):178-182.
    [19]LIMA-POSADA I,PORTAS-CORTS C,PREZ-VILLALVAR,et al.Gender differences in the acute kidney injury to chronic kidney disease transition[J].Sci Rep,2017,7(1):12270.
    [20]KRAUTBAUER S,WIEST R,LIEBISCH G,et al.Associations of systemic sphingolipids with measures of hepatic function in liver cirrhosis are related to cholesterol[J].Prostaglandins Other Lipid Mediat,2017,131:25-32.
    [21]YAN LT,WANG LL,YAO J,et al.Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis B virus infection[J].Medicine(Baltimore),2020,99(8):e19248.
    [22]LIU Y,FAN R,CHEN J,et al.Assessment of renal function and risk factors for renal impairment in patients with hepatitis B virus-related liver cirrhosis[J].J South Med Univ,2014,34(4):472-476.(in Chinese)刘颖,樊蓉,陈简,等.慢性乙型肝炎病毒感染相关肝硬化患者的肾功能及危险因素分析[J].南方医科大学学报,2014,34(4):472-476.
    [23]CHEN YC,SU YC,LI CY,et al.13-year nationwide cohort study of chronic kidney disease risk among treatment-na6ve patients with chronic hepatitis B in Taiwan[J].BMC Nephrol,2015,16:110.
  • 加载中
计量
  • 文章访问数:  1583
  • HTML全文浏览量:  64
  • PDF下载量:  201
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-12-29
  • 出版日期:  2020-07-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回